Mutation and immune profiling of metaplastic breast cancer: Correlation with survival

被引:28
作者
Afkhami, Michelle [1 ]
Schmolze, Daniel [1 ]
Yost, Susan E. [2 ]
Frankel, Paul H. [3 ]
Dagis, Andrew [3 ]
Amanam, Idoroenyi U. [2 ]
Telatar, Milhan [1 ]
Nguyen, Kim [1 ]
Yu, Kim Wai [4 ]
Thehang Luu [2 ]
Pillai, Raju [1 ]
Aoun, Patricia A. [1 ]
Mortimer, Joanne [2 ]
Yuan, Yuan [2 ]
机构
[1] City Hope Comprehens Canc Ctr, Dept Pathol, Duarte, CA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA
[3] City Hope Comprehens Canc Ctr, Dept Biostat, Duarte, CA USA
[4] City Hope Comprehens Canc Ctr, Dept Clin Pharm, Duarte, CA USA
来源
PLOS ONE | 2019年 / 14卷 / 11期
基金
美国国家卫生研究院;
关键词
D O I
10.1371/journal.pone.0224726
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The goal of this study is to characterize the genomic and immune profiles of metaplastic breast cancer (MpBC) and identify the association with survival through an analysis of archived tumor tissue. A next-generation sequencing-based mutational assay (Onco-48) was performed for 21 MpBC patients. Clinicopathologic characteristics were captured, including relapse free survival (RFS) and overall survival (OS). Immunohistochemistry (IHC) for CD3, CD4, CD8, and programmed death-ligand 1 (PD-L1) was also performed. Recurrence free survival (RFS) at 5 years was 57% (95% CI 0.34-0.75) and overall survival (OS) at 5 years was 66% (95% CI 0.41-0.82). The most commonly altered genes were TP53 (68.4%, 13/19), PIK3CA (42.1%, 8/19), and PTEN (15.8%, 3/19. For patients with PIK3CA mutations, RFS and OS were significantly worse than for those without (HR 5.6, 95% CI 1.33-23.1 and HR 8.0, 95% CI 1.53-41.7, respectively). Cox regression estimated that PD L1 expression was associated with worse RFS and OS (HR 1.08, 95% CI 1.01-1.16 and HR 1.05, 95% CI 1.00-1.11, respectively, for an absolute increase in PD-L1 expression of 1%). In conclusion, PIK3CA mutation and PD-L1 expression confer poor prognosis in this cohort of patients with MpBC.
引用
收藏
页数:12
相关论文
共 30 条
  • [1] Adams S, 2015, P 38 ANN CTRC AACR S
  • [2] Considering the Natural Environment in the Creation of Child-Friendly Cities: Implications for Children's Subjective Well-Being
    Adams, Sabirah
    Savahl, Shazly
    Florence, Maria
    Jackson, Kyle
    [J]. CHILD INDICATORS RESEARCH, 2019, 12 (02) : 545 - 567
  • [3] Dramatic response of metaplastic breast cancer to chemo-immunotherapy
    Adams, Sylvia
    [J]. NPJ BREAST CANCER, 2017, 3
  • [4] Alboukadel Kassambara MK, GGPLOT2
  • [5] [Anonymous], 2016, R LANG ENV STAT COMP
  • [6] Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
    Beckers, Rhiannon K.
    Selinger, Christina I.
    Vilain, Ricardo
    Madore, Jason
    Wilmott, James S.
    Harvey, Kate
    Holliday, Anne
    Cooper, Caroline L.
    Robbins, Elizabeth
    Gillett, David
    Kennedy, Catherine W.
    Gluch, Laurence
    Carmalt, Hugh
    Mak, Cindy
    Warrier, Sanjay
    Gee, Harriet E.
    Chan, Charles
    McLean, Anna
    Walker, Emily
    McNeil, Catriona M.
    Beith, Jane M.
    Swarbrick, Alexander
    Scolyer, Richard A.
    O'Toole, Sandra A.
    [J]. HISTOPATHOLOGY, 2016, 69 (01) : 25 - 34
  • [7] Edenfield J, 2016, CLIN BREAST CANC
  • [8] Drugging the p53 pathway: understanding the route to clinical efficacy
    Hoe, Khoo Kian
    Verma, Chandra S.
    Lane, David P.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (03) : 217 - 236
  • [9] Joneja U, 2016, J CLIN PATHOLOGY
  • [10] Safety and efficacy of durvalumab (MEDI4736) a PD-L1 antibody, in urothelial bladder cancer.
    Massard, Christophe
    Gordon, Michael S.
    Sharma, Sunil
    Rafii, Saeed
    Wainberg, Zev A.
    Luke, Jason John
    Curiel, Tyler J.
    Colon-Otero, Gerardo
    Hamid, Omid
    Sanborn, Rachel E.
    O'Donnell, Peter H.
    Drakaki, Alexandra
    Kurland, John
    Rebelatto, Marlon C.
    Jin, Xiaoping
    Blake-Haskins, John A.
    Gupta, Ashok Kumar
    Segal, Neil Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)